Tag: licensing
-
Fox Foundation Supports Parkinson’s Walking Device
A spin-off enterprise from University of Delaware is developing an electronic vibrating device that fits on the feet or ankles of people with Parkinson’s disease to help them walk.
-
Start-Up Raises $10.5M for Precision Immunotherapies
A new biotechnology enterprise developing personalized treatments that harness the immune system to treat cancer is raising $10.5 million in its first venture funding round.
-
MIT Spins-Off 32 Start-Ups in 2018
Research done at Massachusetts Institute of Technology in 2018 led to creation of 32 new start-up enterprises as well as hundreds of licenses and patents.
-
UC-Berkeley to Get New Crispr Patent
University of California in Berkeley will soon receive a new patent for its development of the genome editing process known as Crispr, the latest round in a years-long dispute.
-
Insulin Delivered by Capsule, That’s the Good News
Before we start celebrating the end of injections, we need to deal with a more basic problem facing people with diabetes, namely the rapidly rising cost of insulin.
-
Company to Stop Cancer Spread, Relapse Raises $60.8M
A new company formed to commercialize research that aims to prevent cancer from spreading or recurring is raising $60.75 million in its first venture financing.
-
Natural Enemy Shown Effective Against Staph Bacteria
A clinical trial shows adding a treatment for drug-resistant infections based on the bacteria’s natural enemies kills more Staphylococcus aureus bacteria than standard antibiotics alone.
-
Start-Ups Saying No Thanks to Venture Capital
Yesterday, we reported on 2018 being a banner year for venture capital, but the New York Times says a movement of entrepreneurs is looking for other ways to raise money.
-
Spin-Off Gains Seed Funds for Non-Opioid Pain Drug
A company spun-off from a university medical materials lab received start-up funds to develop a non-opioid surgical pain therapy, including a clinical trial.
-
Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal
Eli Lilly and Co. is licensing a a treatment candidate for Alzheimer’s disease from biopharmaceutical company AC Immune that aims to block accumulation of tau proteins in the brain.